Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series [0.03%]
布雷他丁用于7-羟基密 Ke 酐（7-OH）使用者治疗的回顾性病例系列研究
Emma Fenske,Beth Williams,Laurel Hallock-Koppelman et al.
Emma Fenske et al.
Background: Kratom (Mitragyna speciosa) is increasingly used in the United States as a dietary supplement for pain, mood regulation, and opioid withdrawal. Its alkaloids, mitragynine and 7-hydroxymitragynine (7-OH), demon...
Fertility Beliefs and Menstrual Experiences Among Women Entering Opioid Use Disorder Treatment [0.03%]
阿片类药物使用障碍治疗女性患者的生育观念和月经经历调查研究
Jennifer K Bello,Megan Fuerst,Ximena A Levander et al.
Jennifer K Bello et al.
Objectives: Although many people with OUD may believe they are infertile due to chronic opioid use contributing to menstrual irregularities, minimal data exists on how opioid cessation and OUD treatment may impact fertili...
A Narrative Review of the Metabolic Assessment of Patients on Methadone: An Alternative to Pharmacokinetically Blind Prescribing [0.03%]
美沙酮维持治疗患者的代谢评估述评：一种超越盲目关注药动学的处方方式的方法
John J McCarthy,Martin H Leamon
John J McCarthy
With the increase in fentanyl use, methadone remains one of the standards of care for opioid use disorder and may confer some advantages over buprenorphine. Yet the wide range of patient metabolism makes individual prescribing unpredictable...
Utility of Methadone:Metabolite Ratio as Marker of Methadone Metabolism During Methadone Initiation in Pregnancy [0.03%]
妊娠期开始美沙酮治疗时美沙酮∶代谢产物比率作为美沙酮代谢标志物的效用
Rupsa C Boelig,Dennis J Hand,Artem Belyakov et al.
Rupsa C Boelig et al.
Objectives: The methadone:metabolite ratio (MMR) is a laboratory value assessed pre-dose to discriminate between individuals who are rapid or slow metabolizers. It is a proposed alternative to peak:trough serum methadone ...
Development and Validation of an Image-Based Deep Learning Tool for Identification of Xylazine-Associated Wounds [0.03%]
一种基于图像的深度学习工具的开发和验证，用于识别与羟嗪相关的伤口
Pranav Sompalle,Abeed Sarker,Jennifer Love et al.
Pranav Sompalle et al.
Objectives: Accurate identification of xylazine-associated wounds (XAWs) is critical to providing timely and optimal management; however, discerning the etiology of wounds by appearance alone poses a clinical challenge. T...
Association of Emergency Department Buprenorphine Initiation With Subsequent Pharmacotherapy and Outcomes Among Patients With Opioid Use Disorder [0.03%]
急诊科开始使用布施奈菲定对 opioid 使用障碍患者的后续药物治疗和结局的影响
Peter Treitler,Ayse Akincigil,N Andrew Peterson et al.
Peter Treitler et al.
Objectives: To examine trends in emergency department (ED) buprenorphine initiation and evaluate its association with outcomes in the 180 days following discharge. ...
County-Level Uptake of Take-Home Methadone and Adverse Events Among Commercially Insured Individuals [0.03%]
商业保险人群中的县一级口服美沙酮领取情况及其不良事件
Valentine Wanga,Daniel Cullen,Jonathan Kratchman et al.
Valentine Wanga et al.
Objectives: To maintain access to methadone treatment for opioid use disorder (OUD)-an ongoing public health issue in the United States-the Substance Abuse and Mental Health Services Administration (SAMHSA) implemented po...
Benzodiazepine Tapering: Evidence Limitations and Research Recommendations [0.03%]
苯二氮卓类药物减量治疗：证据局限性和研究建议
Bethea A Kleykamp,Amanda Devoto,Dawn Lindsay et al.
Bethea A Kleykamp et al.
Introduction: Current guidelines often recommend limiting benzodiazepine (BZD) use to 2-4 weeks. However, long-term use remains common, in part due to the challenges of tapering BZDs in the context of physical dependence ...
A Comparison of Neuropsychological Functioning Between Patients With Opioid Use Disorder Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone [0.03%]
长效纳曲酮与丁丙诺啡/纳洛酮治疗的阿片类物质使用障碍患者神经心理功能比较研究
Felipe Castillo,Aimee N C Campbell,Tse-Hwei Choo et al.
Felipe Castillo et al.
Background and objectives: People with opioid use disorder (OUD) who are in safety-sensitive occupations are often not allowed to work if taking methadone or buprenorphine due to concerns about cognitive impairment from o...
Kratom Use and Associations With Mental Health in the United States [0.03%]
美国 kratom 使用与精神健康状况之间的关联性研究
Sean Esteban McCabe,Ralph C Bogan,Kara Dickinson et al.
Sean Esteban McCabe et al.
Objectives: To assess the US lifetime and past-year prevalence of kratom Mitragyna speciosa use and its associations with mental health and DSM-5 substance use disorder (SUD). ...